Subsequently, through the analysis of 10 GC datasets from GEO, we discovered a significant correlation between high expression of ANXA5 and adverse prognosis in GC, including OS, disease-free survival (DFS), recurrence-free survival (RFS), disease-specific survival (DSS), and progression-free survival (PFS) (Fig. 5C-M). The gene discussed is ANXA5; the disease is gastric cancer.